drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00312 | DB00400 | 1,023 | 353 | [
"DDInter1423",
"DDInter843"
] | Pentobarbital | Griseofulvin | A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Dr... | An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections. | Moderate | 1 | [
[
[
1023,
24,
353
]
],
[
[
1023,
6,
8374
],
[
8374,
45,
353
]
],
[
[
1023,
21,
28681
],
[
28681,
60,
353
]
],
[
[
1023,
62,
168
],
[
168,
... | [
[
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Griseofulvin"
]
],
[
[
"Pentobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Com... | Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Griseofulvin (Compound)
Pentobarbital (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Griseofulvin (Compound)
Pentobarbital may cause a minor interaction that can limit clinical effects when taken... |
DB01278 | DB11921 | 1,021 | 1,019 | [
"DDInter1506",
"DDInter492"
] | Pramlintide | Deflazacort | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Moderate | 1 | [
[
[
1021,
24,
1019
]
],
[
[
1021,
63,
1072
],
[
1072,
23,
1019
]
],
[
[
1021,
24,
192
],
[
192,
24,
1019
]
],
[
[
1021,
63,
959
],
[
959,
... | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
... | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens a... |
DB08904 | DB14811 | 375 | 385 | [
"DDInter342",
"DDInter979"
] | Certolizumab pegol | Isatuximab | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Isatuximab (formerly SAR650984) is a humanized, IgG1-derived monoclonal antibody (mAb) produced from a Chinese hamster ovary (CHO) cell line.[L12099,A191799] Structurally, isatuximab is comprised of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains. It is a cytolytic an... | Major | 2 | [
[
[
375,
25,
385
]
],
[
[
375,
25,
1362
],
[
1362,
24,
385
]
],
[
[
375,
64,
377
],
[
377,
24,
385
]
],
[
[
375,
63,
599
],
[
599,
2... | [
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isatuximab"
]
],
[
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
... | Certolizumab pegol may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab
Certolizumab pegol may lead to a major life threatening interaction when taken with Mitomycin and Mitomycin may cause a mod... |
DB00342 | DB11113 | 1,181 | 657 | [
"DDInter1770",
"DDInter307"
] | Terfenadine | Castor oil | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic... | Moderate | 1 | [
[
[
1181,
24,
657
]
],
[
[
1181,
24,
1079
],
[
1079,
24,
657
]
],
[
[
1181,
24,
927
],
[
927,
63,
657
]
],
[
[
1181,
25,
540
],
[
540,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Enc... |
DB00641 | DB11901 | 467 | 913 | [
"DDInter1675",
"DDInter107"
] | Simvastatin | Apalutamide | Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of _Aspergillus terreus_. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endog... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
467,
24,
913
]
],
[
[
467,
24,
112
],
[
112,
23,
913
]
],
[
[
467,
24,
110
],
[
110,
62,
913
]
],
[
[
467,
23,
279
],
[
279,
24,... | [
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab ve... |
DB12267 | DB14840 | 1,476 | 861 | [
"DDInter233",
"DDInter1601"
] | Brigatinib | Ripretinib | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
1476,
24,
861
]
],
[
[
1476,
64,
351
],
[
351,
24,
861
]
],
[
[
1476,
63,
214
],
[
214,
24,
861
]
],
[
[
1476,
24,
1619
],
[
1619,
... | [
[
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib... | Brigatinib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may ca... |
DB00652 | DB01142 | 234 | 1,264 | [
"DDInter1421",
"DDInter593"
] | Pentazocine | Doxepin | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
234,
24,
1264
]
],
[
[
234,
24,
401
],
[
401,
24,
1264
]
],
[
[
234,
63,
1594
],
[
1594,
24,
1264
]
],
[
[
234,
24,
649
],
[
649,
... | [
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Pentazocine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
... | Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Pentazocine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Dox... |
DB06168 | DB06317 | 1,531 | 1,626 | [
"DDInter281",
"DDInter630"
] | Canakinumab | Elotuzumab | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family... | Moderate | 1 | [
[
[
1531,
24,
1626
]
],
[
[
1531,
63,
973
],
[
973,
24,
1626
]
],
[
[
1531,
24,
200
],
[
200,
63,
1626
]
],
[
[
1531,
25,
980
],
[
980,
... | [
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
... | Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans an... |
DB01100 | DB04837 | 1,568 | 649 | [
"DDInter1470",
"DDInter407"
] | Pimozide | Clofedanol | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
1568,
24,
649
]
],
[
[
1568,
63,
1376
],
[
1376,
24,
649
]
],
[
[
1568,
63,
832
],
[
832,
40,
649
]
],
[
[
1568,
64,
401
],
[
401,
... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[
... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamine ... |
DB05015 | DB06688 | 1,077 | 1,430 | [
"DDInter174",
"DDInter1677"
] | Belinostat | Sipuleucel-T | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with... | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared sp... | Moderate | 1 | [
[
[
1077,
24,
1430
]
],
[
[
1077,
63,
869
],
[
869,
24,
1430
]
],
[
[
1077,
25,
676
],
[
676,
63,
1430
]
],
[
[
1077,
24,
1531
],
[
1531,
... | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
... | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Belinostat may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may ca... |
DB00581 | DB09104 | 355 | 286 | [
"DDInter1018",
"DDInter1118"
] | Lactulose | Magnesium hydroxide | Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its p... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Minor | 0 | [
[
[
355,
23,
286
]
],
[
[
355,
24,
820
],
[
820,
23,
286
]
],
[
[
355,
23,
16
],
[
16,
23,
286
]
],
[
[
355,
24,
1326
],
[
1326,
24,... | [
[
[
"Lactulose",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
... | Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Lactulose may cause a minor interaction that can limit clinical effects when taken with Linaclotide and ... |
DB09039 | DB11691 | 1,670 | 1,499 | [
"DDInter629",
"DDInter1258"
] | Eliglustat | Naldemedine | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher dis... | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opi... | Moderate | 1 | [
[
[
1670,
24,
1499
]
],
[
[
1670,
63,
307
],
[
307,
23,
1499
]
],
[
[
1670,
64,
932
],
[
932,
24,
1499
]
],
[
[
1670,
24,
943
],
[
943,
... | [
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Modafinil"
],
[
... | Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine
Eliglustat may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause... |
DB00570 | DB06212 | 147 | 165 | [
"DDInter1936",
"DDInter1833"
] | Vinblastine | Tolvaptan | Antitumor alkaloid isolated from Vinca rosea. (Merck, 11th ed.) | Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009. | Moderate | 1 | [
[
[
147,
24,
165
]
],
[
[
147,
25,
1080
],
[
1080,
1,
165
]
],
[
[
147,
63,
522
],
[
522,
1,
165
]
],
[
[
147,
6,
8374
],
[
8374,
45... | [
[
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
]
],
[
[
"Vinblastine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
],
[
"Conivapta... | Vinblastine may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Tolvaptan (Compound)
Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast (Compound) resembles Tolvaptan (Compound)
Vinblastine (... |
DB00308 | DB05812 | 347 | 1,374 | [
"DDInter901",
"DDInter8"
] | Ibutilide | Abiraterone | Ibutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR). | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Major | 2 | [
[
[
347,
25,
1374
]
],
[
[
347,
21,
29024
],
[
29024,
60,
1374
]
],
[
[
347,
23,
112
],
[
112,
23,
1374
]
],
[
[
347,
25,
1494
],
[
1494,
... | [
[
[
"Ibutilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
],
[
[
"Ibutilide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypertension"
],
[
"Hypertension",
"{u} (Side Effect) is caused by {v} ... | Ibutilide (Compound) causes Hypertension (Side Effect) and Hypertension (Side Effect) is caused by Abiraterone (Compound)
Ibutilide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with ... |
DB00959 | DB14975 | 1,486 | 988 | [
"DDInter1191",
"DDInter1949"
] | Methylprednisolone | Voxelotor | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease. This is a genetically inherited condition most prevalent in the Middle East, Africa, and certain parts of India. Sickle cell disease can lead to excruciating pain, stroke, infection, and various other complications aris... | Moderate | 1 | [
[
[
1486,
24,
988
]
],
[
[
1486,
40,
251
],
[
251,
24,
988
]
],
[
[
1486,
63,
629
],
[
629,
24,
988
]
],
[
[
1486,
24,
214
],
[
214,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Voxelotor"
]
],
[
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u... | Methylprednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Voxelotor
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate int... |
DB01610 | DB05273 | 248 | 507 | [
"DDInter1912",
"DDInter1638"
] | Valganciclovir | Samarium (153Sm) lexidronam | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Moderate | 1 | [
[
[
248,
24,
507
]
],
[
[
248,
40,
563
],
[
563,
24,
507
]
],
[
[
248,
63,
196
],
[
196,
25,
507
]
],
[
[
248,
24,
1626
],
[
1626,
6... | [
[
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
... | Valganciclovir (Compound) resembles Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Altretamine and Altretamine may lead to a ... |
DB00379 | DB01362 | 143 | 497 | [
"DDInter1206",
"DDInter960"
] | Mexiletine | Iohexol | Antiarrhythmic agent pharmacologically similar to lidocaine. It may have some anticonvulsant properties. | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
143,
25,
497
]
],
[
[
143,
21,
28681
],
[
28681,
60,
497
]
],
[
[
143,
63,
1010
],
[
1010,
25,
497
]
],
[
[
143,
24,
1503
],
[
1503,
... | [
[
[
"Mexiletine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Mexiletine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused b... | Mexiletine (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Mexiletine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may lead to a major life threatening interaction when taken with Iohexol
Mex... |
DB00396 | DB06292 | 989 | 549 | [
"DDInter1529",
"DDInter474"
] | Progesterone | Dapagliflozin | Progesterone is a hormone that occurs naturally in females, and is essential for endometrial receptivity, embryo implantation, and the successful establishment of pregnancy. A low progesterone concentration or an insufficient response to progesterone can cause infertility and pregnancy loss. Progesterone is used in var... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
989,
24,
549
]
],
[
[
989,
24,
1344
],
[
1344,
40,
549
]
],
[
[
989,
6,
9842
],
[
9842,
45,
549
]
],
[
[
989,
21,
28882
],
[
28882,
... | [
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Progesterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
]... | Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Progesterone (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Dapagliflozin (Compound)
Progesterone (Compound) causes Body temperature in... |
DB01191 | DB11732 | 1,039 | 1,097 | [
"DDInter518",
"DDInter1027"
] | Dexfenfluramine | Lasmiditan | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Major | 2 | [
[
[
1039,
25,
1097
]
],
[
[
1039,
24,
478
],
[
478,
24,
1097
]
],
[
[
1039,
24,
1421
],
[
1421,
63,
1097
]
],
[
[
1039,
63,
13
],
[
13,
... | [
[
[
"Dexfenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lasmiditan"
]
],
[
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"N... | Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban an... |
DB00275 | DB11827 | 217 | 433 | [
"DDInter1330",
"DDInter669"
] | Olmesartan | Ertugliflozin | Olmesartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [valsartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, w... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
217,
24,
433
]
],
[
[
217,
24,
251
],
[
251,
24,
433
]
],
[
[
217,
1,
240
],
[
240,
24,
433
]
],
[
[
217,
63,
176
],
[
176,
24,
... | [
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Olmesartan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
... | Olmesartan may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Olmesartan (Compound) resembles Losartan (Compound) and Losartan may cause a moderate interaction that ... |
DB01168 | DB01233 | 1,053 | 1,311 | [
"DDInter1526",
"DDInter1197"
] | Procarbazine | Metoclopramide | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Diabetic gastroparesis is a condition that causes frequent nausea and vomiting, which has a negative impact on quality of life and poses a significant burden on the healthcare system. Metoclopramide is a dopamine antagonist used to treat nausea and vomiting that may be associated with diabetic gastroparesis in addition... | Moderate | 1 | [
[
[
1053,
24,
1311
]
],
[
[
1053,
21,
28691
],
[
28691,
60,
1311
]
],
[
[
1053,
64,
817
],
[
817,
23,
1311
]
],
[
[
1053,
63,
1252
],
[
12... | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
]
],
[
[
"Procarbazine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effec... | Procarbazine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Metoclopramide (Compound)
Procarbazine may lead to a major life threatening interaction when taken with Dopamine and Dopamine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Pro... |
DB00731 | DB00980 | 1,144 | 969 | [
"DDInter1269",
"DDInter1564"
] | Nateglinide | Ramelteon | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Moderate | 1 | [
[
[
1144,
24,
969
]
],
[
[
1144,
6,
8374
],
[
8374,
45,
969
]
],
[
[
1144,
21,
28714
],
[
28714,
60,
969
]
],
[
[
1144,
24,
1619
],
[
1619... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ramelteon"
]
],
[
[
"Nateglinide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Nateglinide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Nateglinide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Ramelteon (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucapa... |
DB00305 | DB01181 | 377 | 1,532 | [
"DDInter1232",
"DDInter906"
] | Mitomycin | Ifosfamide | Mitomycin is an antineoplastic antibiotic first isolated by Japanese microbiologists in the 1950s from cultures of _Streptomyces caespitosus_.[L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of th... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
377,
24,
1532
]
],
[
[
377,
7,
5415
],
[
5415,
46,
1532
]
],
[
[
377,
54,
19138
],
[
19138,
15,
1532
]
],
[
[
377,
18,
2976
],
[
2976,... | [
[
[
"Mitomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Mitomycin",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (C... | Mitomycin (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Ifosfamide (Compound)
Mitomycin (Compound) is included by Alkylating Activity (Pharmacologic Class) and Alkylating Activity (Pharmacologic Class) includes Ifosfamide (Compound)
Mitomycin (Compound) downregulates STUB1 (Gene) and STUB1 (G... |
DB01149 | DB06176 | 851 | 1,342 | [
"DDInter1274",
"DDInter1616"
] | Nefazodone | Romidepsin | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
851,
24,
1342
]
],
[
[
851,
25,
1491
],
[
1491,
63,
1342
]
],
[
[
851,
24,
820
],
[
820,
24,
1342
]
],
[
[
851,
63,
51
],
[
51,
... | [
[
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Nefazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaur... | Nefazodone may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may ca... |
DB01050 | DB01165 | 848 | 1,539 | [
"DDInter900",
"DDInter1325"
] | Ibuprofen | Ofloxacin | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally p... | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
848,
24,
1539
]
],
[
[
848,
63,
1467
],
[
1467,
1,
1539
]
],
[
[
848,
24,
945
],
[
945,
40,
1539
]
],
[
[
848,
6,
10417
],
[
10417,
... | [
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enoxacin"
],
[
"... | Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Ibup... |
DB00938 | DB01142 | 455 | 1,264 | [
"DDInter1635",
"DDInter593"
] | Salmeterol | Doxepin | Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, [salbutamol]. Salm... | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Moderate | 1 | [
[
[
455,
24,
1264
]
],
[
[
455,
63,
508
],
[
508,
24,
1264
]
],
[
[
455,
24,
401
],
[
401,
24,
1264
]
],
[
[
455,
6,
8374
],
[
8374,
... | [
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
]
],
[
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
... | Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethaz... |
DB01234 | DB08822 | 1,220 | 911 | [
"DDInter513",
"DDInter156"
] | Dexamethasone | Azilsartan medoxomil | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Azilsartan medoxomil is a prodrug that is broken down to azilsartan, which belongs in the angiotensin-receptor blocking (ARB) drug class. It is a selective AT1 subtype angiotensin II receptor antagonist. Azilsartan medoxomil is a relatively recently-developed antihypertensive drug that was first approved by the FDA in ... | Moderate | 1 | [
[
[
1220,
24,
911
]
],
[
[
1220,
63,
217
],
[
217,
1,
911
]
],
[
[
1220,
21,
28880
],
[
28880,
60,
911
]
],
[
[
1220,
24,
1450
],
[
1450,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azilsartan medoxomil"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olmesartan"... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Olmesartan and Olmesartan (Compound) resembles Azilsartan medoxomil (Compound)
Dexamethasone (Compound) causes Angiopathy (Side Effect) and Angiopathy (Side Effect) is caused by Azilsartan medoxomil (Compound)
Dexamethasone ma... |
DB00675 | DB14840 | 888 | 861 | [
"DDInter1744",
"DDInter1601"
] | Tamoxifen | Ripretinib | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA... | Moderate | 1 | [
[
[
888,
24,
861
]
],
[
[
888,
25,
351
],
[
351,
24,
861
]
],
[
[
888,
24,
214
],
[
214,
24,
861
]
],
[
[
888,
63,
353
],
[
353,
24,... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",... | Tamoxifen may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may caus... |
DB00683 | DB06168 | 1,382 | 1,531 | [
"DDInter1212",
"DDInter281"
] | Midazolam | Canakinumab | Midazolam is a short-acting hypnotic-sedative drug with anxiolytic, muscle relaxant, anticonvulsant, sedative, hypnotic, and amnesic properties. It belongs to a class of drugs called _benzodiazepines_. This drug is unique from others in this class due to its rapid onset of effects and short duration of action. Midazola... | Canakinumab is a recombinant, human anti-human-IL-1β monoclonal antibody that belongs to the IgG1/κ isotype subclass. It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. B... | Moderate | 1 | [
[
[
1382,
24,
1531
]
],
[
[
1382,
1,
523
],
[
523,
24,
1531
]
],
[
[
1382,
24,
1362
],
[
1362,
63,
1531
]
],
[
[
1382,
24,
1213
],
[
1213,... | [
[
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
]
],
[
[
"Midazolam",
"{u} (Compound) resembles {v} (Compound)",
"Alprazolam"
],
[
"Alprazolam",
"{u} may cause a moderate... | Midazolam (Compound) resembles Alprazolam (Compound) and Alprazolam may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab
Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exac... |
DB01232 | DB09038 | 1,327 | 1,450 | [
"DDInter1640",
"DDInter636"
] | Saquinavir | Empagliflozin | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1327,
24,
1450
]
],
[
[
1327,
64,
485
],
[
485,
24,
1450
]
],
[
[
1327,
24,
659
],
[
659,
63,
1450
]
],
[
[
1327,
63,
1179
],
[
1179,
... | [
[
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentam... | Saquinavir may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may c... |
DB00019 | DB00059 | 1,257 | 1,560 | [
"DDInter1405",
"DDInter1404"
] | Pegfilgrastim | Pegaspargase | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti... | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Moderate | 1 | [
[
[
1257,
24,
1560
]
],
[
[
1257,
24,
372
],
[
372,
63,
1560
]
],
[
[
1257,
63,
1451
],
[
1451,
24,
1560
]
],
[
[
1257,
24,
1648
],
[
1648... | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],... | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Interferon ... |
DB06016 | DB12010 | 1,508 | 214 | [
"DDInter300",
"DDInter785"
] | Cariprazine | Fostamatinib | Cariprazine is an atypical antipsychotic agent and a piperazine derivative that was first developed in Hungary. It works as a partial agonist at central dopamine D2, dopamine D3, and serotonin 5-HT<sub>1A</sub> receptors and as an antagonist at serotonin 5-HT<sub>2A</sub> receptors. Cariprazine has been investigated in... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1508,
24,
214
]
],
[
[
1508,
63,
723
],
[
723,
24,
214
]
],
[
[
1508,
24,
1250
],
[
1250,
24,
214
]
],
[
[
1508,
24,
1017
],
[
1017,
... | [
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cariprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cariprazine may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Paz... |
DB00595 | DB00713 | 1,545 | 1,138 | [
"DDInter1374",
"DDInter1354"
] | Oxytetracycline | Oxacillin | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | An antibiotic similar to [flucloxacillin] used in resistant staphylococci infections. | Moderate | 1 | [
[
[
1545,
24,
1138
]
],
[
[
1545,
63,
916
],
[
916,
1,
1138
]
],
[
[
1545,
24,
319
],
[
319,
1,
1138
]
],
[
[
1545,
24,
1249
],
[
1249,
... | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxacillin"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicloxacillin"
... | Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Dicloxacillin and Dicloxacillin (Compound) resembles Oxacillin (Compound)
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Amoxicillin and Amoxicillin (Compound) resembles Oxaci... |
DB09472 | DB11796 | 1,383 | 1,612 | [
"DDInter1693",
"DDInter786"
] | Sodium sulfate | Fostemsavir | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate... | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1383,
24,
1612
]
],
[
[
1383,
64,
1424
],
[
1424,
24,
1612
]
],
[
[
1383,
24,
823
],
[
823,
63,
1612
]
],
[
[
1383,
63,
1264
],
[
1264... | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Sodium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quin... | Sodium sulfate may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazo... |
DB00731 | DB01404 | 1,144 | 757 | [
"DDInter1269",
"DDInter820"
] | Nateglinide | Ginseng | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Ginseng is promoted as an adaptogen (a product that increases the body's resistance to stress), one which can to a certain extent be supported with reference to its anticarcinogenic and antioxidant properties. Ginseng is also known to contain phytoestrogens. | Moderate | 1 | [
[
[
1144,
24,
757
]
],
[
[
1144,
63,
245
],
[
245,
24,
757
]
],
[
[
1144,
24,
170
],
[
170,
24,
757
]
],
[
[
1144,
24,
1344
],
[
1344,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginseng"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Ginseng
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sita... |
DB01320 | DB08881 | 651 | 868 | [
"DDInter783",
"DDInter1925"
] | Fosphenytoin | Vemurafenib | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Major | 2 | [
[
[
651,
25,
868
]
],
[
[
651,
6,
8374
],
[
8374,
45,
868
]
],
[
[
651,
21,
29106
],
[
29106,
60,
868
]
],
[
[
651,
62,
608
],
[
608,
... | [
[
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
]
],
[
[
"Fosphenytoin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ve... | Fosphenytoin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vemurafenib (Compound)
Fosphenytoin (Compound) causes Myalgia (Side Effect) and Myalgia (Side Effect) is caused by Vemurafenib (Compound)
Fosphenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lid... |
DB00950 | DB11718 | 1,413 | 927 | [
"DDInter732",
"DDInter640"
] | Fexofenadine | Encorafenib | Fexofenadine is an over-the-counter second-generation antihistamine used in the treatment of various allergic symptoms. It is selective for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier - this is in contrast to previous first-generation antihistamin... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1413,
24,
927
]
],
[
[
1413,
24,
165
],
[
165,
24,
927
]
],
[
[
1413,
24,
484
],
[
484,
63,
927
]
],
[
[
1413,
40,
543
],
[
543,
... | [
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Fexofenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolvaptan"
],
... | Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Tolvaptan and Tolvaptan may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and En... |
DB06589 | DB06636 | 1,250 | 1,623 | [
"DDInter1400",
"DDInter980"
] | Pazopanib | Isavuconazonium | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1250,
24,
1623
]
],
[
[
1250,
24,
466
],
[
466,
62,
1623
]
],
[
[
1250,
63,
1419
],
[
1419,
24,
1623
]
],
[
[
1250,
64,
1487
],
[
1487... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Ima... |
DB00041 | DB00186 | 1,648 | 905 | [
"DDInter38",
"DDInter1092"
] | Aldesleukin | Lorazepam | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Moderate | 1 | [
[
[
1648,
24,
905
]
],
[
[
1648,
24,
87
],
[
87,
1,
905
]
],
[
[
1648,
25,
695
],
[
695,
1,
905
]
],
[
[
1648,
24,
1242
],
[
1242,
6... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorazepam"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Amoxapine and Amoxapine (Compound) resembles Lorazepam (Compound)
Aldesleukin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Lorazepam (Compound)
Aldesleukin may cau... |
DB00333 | DB00341 | 576 | 1,242 | [
"DDInter1166",
"DDInter343"
] | Methadone | Cetirizine | Methadone is a potent synthetic analgesic that works as a full µ-opioid receptor (MOR) agonist and N-methyl-d-aspartate (NMDA) receptor antagonist. As a full MOR agonist, methadone mimics the natural effects of the body's opioids, endorphins, and enkephalins through the release of neurotransmitters involved in pain tra... | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms , . One of the most common uses for this drug is for a condition called _alle... | Moderate | 1 | [
[
[
576,
24,
1242
]
],
[
[
576,
24,
537
],
[
537,
63,
1242
]
],
[
[
576,
1,
1413
],
[
1413,
1,
1242
]
],
[
[
576,
35,
543
],
[
543,
... | [
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cetirizine"
]
],
[
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Methadone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Methadone (Compound) resembles Fexofenadine (Compound) and Fexofenadine (Compound) resembles Cetirizine (Compound)
... |
DB01208 | DB06203 | 945 | 1,002 | [
"DDInter1705",
"DDInter51"
] | Sparfloxacin | Alogliptin | Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
945,
24,
1002
]
],
[
[
945,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
945,
21,
28873
],
[
28873,
60,
1002
]
],
[
[
945,
64,
401
],
[
401,
... | [
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
... | Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Sparfloxacin (Compound) causes Pancreatitis (Side Effect) and Pancreatitis (Side Effect) is caused by Alogliptin (Compound)
Sparfloxacin may lead to a major... |
DB06718 | DB08880 | 1,687 | 1,510 | [
"DDInter1709",
"DDInter1771"
] | Stanozolol | Teriflunomide | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of h... | Major | 2 | [
[
[
1687,
25,
1510
]
],
[
[
1687,
63,
1144
],
[
1144,
24,
1510
]
],
[
[
1687,
24,
242
],
[
242,
63,
1510
]
],
[
[
1687,
40,
1197
],
[
1197... | [
[
[
"Stanozolol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
]
],
[
[
"Stanozolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nategl... | Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Teriflunomide
Stanozolol may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and R... |
DB08896 | DB09075 | 292 | 498 | [
"DDInter1576",
"DDInter621"
] | Regorafenib | Edoxaban | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
292,
25,
498
]
],
[
[
292,
24,
41
],
[
41,
24,
498
]
],
[
[
292,
63,
109
],
[
109,
24,
498
]
],
[
[
292,
24,
1017
],
[
1017,
63,... | [
[
[
"Regorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levom... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine ... |
DB01211 | DB09065 | 609 | 760 | [
"DDInter393",
"DDInter424"
] | Clarithromycin | Cobicistat | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Moderate | 1 | [
[
[
609,
24,
760
]
],
[
[
609,
62,
479
],
[
479,
23,
760
]
],
[
[
609,
23,
1627
],
[
1627,
23,
760
]
],
[
[
609,
64,
1230
],
[
1230,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Cannabidiol and Canna... |
DB01132 | DB08815 | 1,130 | 154 | [
"DDInter1472",
"DDInter1104"
] | Pioglitazone | Lurasidone | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S. Food and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. | Moderate | 1 | [
[
[
1130,
24,
154
]
],
[
[
1130,
6,
8374
],
[
8374,
45,
154
]
],
[
[
1130,
21,
29579
],
[
29579,
60,
154
]
],
[
[
1130,
24,
1033
],
[
1033... | [
[
[
"Pioglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
]
],
[
[
"Pioglitazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Pioglitazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lurasidone (Compound)
Pioglitazone (Compound) causes Breast disorder (Side Effect) and Breast disorder (Side Effect) is caused by Lurasidone (Compound)
Pioglitazone may cause a moderate interaction that could exacerbate diseases when taken with A... |
DB00835 | DB06204 | 100 | 768 | [
"DDInter245",
"DDInter1746"
] | Brompheniramine | Tapentadol | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA... | Moderate | 1 | [
[
[
100,
24,
768
]
],
[
[
100,
6,
10215
],
[
10215,
45,
768
]
],
[
[
100,
63,
1123
],
[
1123,
24,
768
]
],
[
[
100,
24,
1532
],
[
1532,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Brompheniramine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} ... | Brompheniramine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound)
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Propantheline and Propantheline may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
... |
DB01246 | DB09078 | 820 | 1,228 | [
"DDInter45",
"DDInter1036"
] | Alimemazine | Lenvatinib | A phenothiazine derivative that is used as an antipruritic. | Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progressi... | Moderate | 1 | [
[
[
820,
24,
1228
]
],
[
[
820,
62,
112
],
[
112,
23,
1228
]
],
[
[
820,
63,
1100
],
[
1100,
24,
1228
]
],
[
[
820,
24,
938
],
[
938,
... | [
[
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
]
],
[
[
"Alimemazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[... | Alimemazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lenvatinib
Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Venlafaxine and V... |
DB00104 | DB00640 | 966 | 1,585 | [
"DDInter1323",
"DDInter31"
] | Octreotide | Adenosine | Acromegaly is a disorder caused by excess growth hormone (GH), increasing the growth of body tissues and causing metabolic dysfunction. In most cases, it results from an anterior pituitary growth hormone-releasing tumor. Typically, the feet, hands, and face grow abnormally large; organomegaly and insulin resistance may... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Moderate | 1 | [
[
[
966,
24,
1585
]
],
[
[
966,
21,
28676
],
[
28676,
60,
1585
]
],
[
[
966,
24,
484
],
[
484,
63,
1585
]
],
[
[
966,
24,
351
],
[
351,
... | [
[
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Octreotide",
"{u} (Compound) causes {v} (Side Effect)",
"Nervousness"
],
[
"Nervousness",
"{u} (Side Effect) is c... | Octreotide (Compound) causes Nervousness (Side Effect) and Nervousness (Side Effect) is caused by Adenosine (Compound)
Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Ad... |
DB00005 | DB06674 | 1,057 | 908 | [
"DDInter687",
"DDInter837"
] | Etanercept | Golimumab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Major | 2 | [
[
[
1057,
25,
908
]
],
[
[
1057,
23,
1193
],
[
1193,
62,
908
]
],
[
[
1057,
23,
1461
],
[
1461,
23,
908
]
],
[
[
1057,
24,
336
],
[
336,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluc... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Golimumab
Etanercept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitami... |
DB00208 | DB06081 | 1,018 | 1,046 | [
"DDInter1804",
"DDInter286"
] | Ticlopidine | Caplacizumab | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
1018,
25,
1046
]
],
[
[
1018,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
1018,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1018,
24,
1412
],
[
14... | [
[
[
"Ticlopidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmeric",... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfe... |
DB05676 | DB12887 | 1,513 | 1,598 | [
"DDInter111",
"DDInter1750"
] | Apremilast | Tazemetostat | Apremilast, also known as Otezla, is a phosphodiesterase 4 (PDE4) inhibitor used to treat various types of symptoms resulting from certain inflammatory autoimmune diseases. It belongs to the same drug class as [Roflumilast] and [Crisaborole].[A181244,L7495] Initially approved in 2014, it is marketed by Celgene. In July... | Tazemetostat is a methyltransferase inhibitor used to treat metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Tazemetostat was first named in literature as EPZ-6438. Tazemetaostat was granted FDA approval on 23 January 2020. | Moderate | 1 | [
[
[
1513,
24,
1598
]
],
[
[
1513,
24,
1476
],
[
1476,
24,
1598
]
],
[
[
1513,
63,
1324
],
[
1324,
24,
1598
]
],
[
[
1513,
24,
982
],
[
982... | [
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
]
],
[
[
"Apremilast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
... | Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat
Apremilast may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Tr... |
DB00075 | DB01156 | 541 | 593 | [
"DDInter1250",
"DDInter252"
] | Muromonab | Bupropion | Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens. More specifically it is a purified murine (mouse) monoclonal antibody, directed against the CD3 (T3) receptor on the surface of human T-cells (T-lymphocytes) cultured using the murine ascites method. Muromonab is 93% monomeric immune globulin G type... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
541,
25,
593
]
],
[
[
541,
24,
958
],
[
958,
63,
593
]
],
[
[
541,
24,
1503
],
[
1503,
25,
593
]
],
[
[
541,
25,
1510
],
[
1510,
... | [
[
[
"Muromonab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Muromonab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
],
[
"Ginkgo bil... | Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba and Ginkgo biloba may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Muromonab may cause a moderate interaction that could exacerbate diseases when taken with Lindane and Lindan... |
DB00341 | DB01176 | 1,242 | 537 | [
"DDInter343",
"DDInter453"
] | Cetirizine | Cyclizine | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Moderate | 1 | [
[
[
1242,
24,
537
]
],
[
[
1242,
40,
11304
],
[
11304,
1,
537
]
],
[
[
1242,
24,
104
],
[
104,
1,
537
]
],
[
[
1242,
1,
1321
],
[
1321,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound)",
"Ifenprodil"
],
[
"Ifenprodil",
"{u} (Compound) resembles... | Cetirizine (Compound) resembles Ifenprodil (Compound) and Ifenprodil (Compound) resembles Cyclizine (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Cyclizine (Compound)
Cetirizine (Compound) resembles Prochlorperazi... |
DB00366 | DB01209 | 1,594 | 1,359 | [
"DDInter600",
"DDInter531"
] | Doxylamine | Dezocine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Dezocine is a partial opiate drug and is used for pain management. Dezocine is a very effective alternative to fentanyl when administered during outpatient laparoscopy, although is associated with an increased incidence of postoperative nausea. | Moderate | 1 | [
[
[
1594,
24,
1359
]
],
[
[
1594,
24,
234
],
[
234,
1,
1359
]
],
[
[
1594,
24,
717
],
[
717,
24,
1359
]
],
[
[
1594,
74,
701
],
[
701,
... | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dezocine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentazocine"
],
[
... | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Pentazocine and Pentazocine (Compound) resembles Dezocine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide and Trimethobenzamide may cause a moderate interact... |
DB01099 | DB08913 | 1,272 | 1,186 | [
"DDInter744",
"DDInter1561"
] | Flucytosine | Radium Ra 223 dichloride | A fluorinated cytosine analog that is used as an antifungal agent. | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1272,
24,
1186
]
],
[
[
1272,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
1272,
63,
1287
],
[
1287,
24,
1186
]
],
[
[
1272,
24,
4
],
[
4,
... | [
[
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Flucytosine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effec... | Flucytosine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when ... |
DB00358 | DB01211 | 1,010 | 609 | [
"DDInter1140",
"DDInter393"
] | Mefloquine | Clarithromycin | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1010,
24,
609
]
],
[
[
1010,
63,
1570
],
[
1570,
24,
609
]
],
[
[
1010,
6,
4973
],
[
4973,
45,
609
]
],
[
[
1010,
7,
8733
],
[
8733,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
],
... | Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Mefloquine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clarithromycin (Compound)
Mefloqui... |
DB00560 | DB00992 | 753 | 842 | [
"DDInter1805",
"DDInter1182"
] | Tigecycline | Methyl aminolevulinate (topical) | Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17,... | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Moderate | 1 | [
[
[
753,
24,
842
]
],
[
[
753,
64,
1101
],
[
1101,
24,
842
]
],
[
[
753,
25,
213
],
[
213,
36,
842
]
],
[
[
753,
64,
1101
],
[
1101,
... | [
[
[
"Tigecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
]
],
[
[
"Tigecycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
... | Tigecycline may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate
Tigecycline may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate... |
DB00992 | DB12035 | 842 | 943 | [
"DDInter1182",
"DDInter1641"
] | Methyl aminolevulinate (topical) | Sarecycline | Methyl 5-aminolevulinate is the methyl ester of 5-aminolevulinic acid. A prodrug, it is metabolised to protoporphyrin IX, a photosensitizer, and is used in the photodynamic treatment of non-melanoma skin cancer (including basal cell carcinoma). Topical application (often as the hydrochloride salt) results in an accumul... | Sarecycline is a semi-synthetic derivative of tetracycline that was initially discovered by Paratek Pharmaceuticals from Boston, MA but then licensed to Warner Chilcott of Rockaway, NJ in July of 2007 . After completing various phase-II and phase-III trials demonstrating its effectiveness in treating moderate to severe... | Moderate | 1 | [
[
[
842,
24,
943
]
],
[
[
842,
24,
392
],
[
392,
24,
943
]
],
[
[
842,
63,
1195
],
[
1195,
24,
943
]
],
[
[
842,
75,
213
],
[
213,
2... | [
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
]
],
[
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"La... | Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline
Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00559 | DB00675 | 152 | 888 | [
"DDInter223",
"DDInter1744"
] | Bosentan | Tamoxifen | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Moderate | 1 | [
[
[
152,
24,
888
]
],
[
[
152,
6,
10083
],
[
10083,
45,
888
]
],
[
[
152,
21,
29152
],
[
29152,
60,
888
]
],
[
[
152,
24,
1135
],
[
1135,
... | [
[
[
"Bosentan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"ABCB11"
],
[
"ABCB11",
"{u} (Gene) is bound by {v} (Compound)",
... | Bosentan (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Tamoxifen (Compound)
Bosentan (Compound) causes Thirst (Side Effect) and Thirst (Side Effect) is caused by Tamoxifen (Compound)
Bosentan may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause... |
DB00877 | DB09065 | 629 | 760 | [
"DDInter1678",
"DDInter424"
] | Sirolimus | Cobicistat | Sirolimus, also known as rapamycin, is a macrocyclic lactone antibiotic produced by bacteria _Streptomyces hygroscopicus_, which was isolated from the soil of the Vai Atari region of Rapa Nui (Easter Island). It was first isolated and identified as an antifungal agent with potent anticandida activity; however, after it... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
629,
25,
760
]
],
[
[
629,
24,
1627
],
[
1627,
23,
760
]
],
[
[
629,
63,
1230
],
[
1230,
23,
760
]
],
[
[
629,
23,
907
],
[
907,
... | [
[
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol... | Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopr... |
DB00023 | DB00759 | 305 | 1,620 | [
"DDInter127",
"DDInter1783"
] | Asparaginase Escherichia coli | Tetracycline | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | Moderate | 1 | [
[
[
305,
24,
1620
]
],
[
[
305,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
305,
24,
45
],
[
45,
62,
1620
]
],
[
[
305,
24,
1254
],
[
1254,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Didanosine and Didano... |
DB01619 | DB12161 | 830 | 730 | [
"DDInter1441",
"DDInter512"
] | Phenindamine | Deutetrabenazine | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine ... | Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated . The presence of deuterium in deutetrabenazine increases the half-lives ... | Moderate | 1 | [
[
[
830,
24,
730
]
],
[
[
830,
63,
100
],
[
100,
24,
730
]
],
[
[
830,
1,
1219
],
[
1219,
24,
730
]
],
[
[
830,
24,
407
],
[
407,
24... | [
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
]
],
[
[
"Phenindamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"
... | Phenindamine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine
Phenindamine (Compound) resembles Azatadine (Compound) and Azatadine may cause a moderate inte... |
DB00619 | DB09061 | 1,419 | 1,627 | [
"DDInter909",
"DDInter284"
] | Imatinib | Cannabidiol | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated wi... | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical i... | Minor | 0 | [
[
[
1419,
23,
1627
]
],
[
[
1419,
24,
723
],
[
723,
23,
1627
]
],
[
[
1419,
24,
760
],
[
760,
62,
1627
]
],
[
[
1419,
63,
600
],
[
600,
... | [
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"... | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat ... |
DB00022 | DB01381 | 268 | 958 | [
"DDInter1408",
"DDInter819"
] | Peginterferon alfa-2b | Ginkgo biloba | Peginterferon alfa-2b is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
268,
24,
958
]
],
[
[
268,
24,
126
],
[
126,
24,
958
]
],
[
[
268,
63,
491
],
[
491,
24,
958
]
],
[
[
268,
25,
593
],
[
593,
24,... | [
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Peginterferon alfa-2b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Wa... | Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Peginterferon alfa-2b may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00092 | DB00544 | 58 | 970 | [
"DDInter40",
"DDInter757"
] | Alefacept | Fluorouracil | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
58,
24,
970
]
],
[
[
58,
24,
132
],
[
132,
1,
970
]
],
[
[
58,
24,
147
],
[
147,
62,
970
]
],
[
[
58,
24,
1686
],
[
1686,
63,
... | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Uracil mustard"
],
... | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Uracil mustard and Uracil mustard (Compound) resembles Fluorouracil (Compound)
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction tha... |
DB00186 | DB01205 | 905 | 1,404 | [
"DDInter1092",
"DDInter748"
] | Lorazepam | Flumazenil | Lorazepam is a short-acting and rapidly cleared benzodiazepine used commonly as a sedative and anxiolytic. It was developed by DJ Richards, presented and marketed initially by Wyeth Pharmaceuticals in the USA in 1977. The first historic FDA label approval is reported in 1985 by the company Mutual Pharm. | Fumazenil is an imidazobenzodiazepine derivative and a potent benzodiazepine receptor antagonist that competitively inhibits the activity at the benzodiazepine recognition site on the GABA/benzodiazepine receptor complex, thereby reversing the effects of benzodiazepine on the central nervous system. | Moderate | 1 | [
[
[
905,
24,
1404
]
],
[
[
905,
6,
6506
],
[
6506,
45,
1404
]
],
[
[
905,
21,
29003
],
[
29003,
60,
1404
]
],
[
[
905,
40,
1382
],
[
1382,... | [
[
[
"Lorazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flumazenil"
]
],
[
[
"Lorazepam",
"{u} (Compound) binds {v} (Gene)",
"GABRG2"
],
[
"GABRG2",
"{u} (Gene) is bound by {v} (Compound)",
... | Lorazepam (Compound) binds GABRG2 (Gene) and GABRG2 (Gene) is bound by Flumazenil (Compound)
Lorazepam (Compound) causes Aggression (Side Effect) and Aggression (Side Effect) is caused by Flumazenil (Compound)
Lorazepam (Compound) resembles Midazolam (Compound) and Midazolam may cause a moderate interaction that could ... |
DB08865 | DB15328 | 1,593 | 829 | [
"DDInter448",
"DDInter1896"
] | Crizotinib | Ubrogepant | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor ... | Moderate | 1 | [
[
[
1593,
24,
829
]
],
[
[
1593,
25,
1476
],
[
1476,
24,
829
]
],
[
[
1593,
24,
1468
],
[
1468,
24,
829
]
],
[
[
1593,
63,
578
],
[
578,
... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib... | Crizotinib may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a ... |
DB00055 | DB11071 | 834 | 1,004 | [
"DDInter605",
"DDInter1449"
] | Drotrecogin alfa | Phenyl salicylate | Drotrecogin alfa is activated human protein C that is synthesized by recombinant DNA technology. It is a glycoprotein of approximately 55 kilodalton molecular weight, consisting of a heavy chain and a light chain linked by a disulfide bond. Drotrecogin alfa was withdrawn from the market after a major study indicated th... | Phenyl salicylate is a 2-hydroxybenzoic acid phenyl ester. It is utilized in some manufacturing processes of polymers, lacquers, adhesives, waxes, as well as polishes. It is an active ingredient in some pharmaceutical products as a mild analgesic for pain relief by releasing salicylate (found in ). Phenyl salicylate ma... | Moderate | 1 | [
[
[
834,
24,
1004
]
],
[
[
834,
25,
500
],
[
500,
24,
1004
]
],
[
[
834,
24,
1074
],
[
1074,
24,
1004
]
],
[
[
834,
25,
235
],
[
235,
... | [
[
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenyl salicylate"
]
],
[
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
... | Drotrecogin alfa may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Phenyl salicylate
Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-123 and ... |
DB01144 | DB01169 | 1,326 | 57 | [
"DDInter540",
"DDInter120"
] | Diclofenamide | Arsenic trioxide | A carbonic anhydrase inhibitor that is used in the treatment of glaucoma. | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Major | 2 | [
[
[
1326,
25,
57
]
],
[
[
1326,
24,
603
],
[
603,
63,
57
]
],
[
[
1326,
63,
480
],
[
480,
24,
57
]
],
[
[
1326,
63,
167
],
[
167,
25... | [
[
[
"Diclofenamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
]
],
[
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
... | Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Arsenic trioxide
Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken ... |
DB00543 | DB06767 | 87 | 732 | [
"DDInter82",
"DDInter80"
] | Amoxapine | Ammonium chloride | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Ammonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions. | Minor | 0 | [
[
[
87,
23,
732
]
],
[
[
87,
24,
1264
],
[
1264,
23,
732
]
],
[
[
87,
25,
22
],
[
22,
23,
732
]
],
[
[
87,
24,
1264
],
[
1264,
64,
... | [
[
[
"Amoxapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ammonium chloride"
]
],
[
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
... | Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a minor interaction that can limit clinical effects when taken with Ammonium chloride
Amoxapine may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a min... |
DB00341 | DB01149 | 1,242 | 851 | [
"DDInter343",
"DDInter1274"
] | Cetirizine | Nefazodone | Cetirizine, also commonly known as _Zyrtec_, is an orally active second-generation histamine H1 antagonist proven effective in the treatment of various allergic symptoms, such as sneezing, coughing, nasal congestion, hives, and other symptoms,. One of the most common uses for this drug is for a condition called _allerg... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
1242,
24,
851
]
],
[
[
1242,
35,
252
],
[
252,
40,
851
]
],
[
[
1242,
24,
1178
],
[
1178,
1,
851
]
],
[
[
1242,
24,
673
],
[
673,
... | [
[
[
"Cetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Cetirizine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken w... | Cetirizine (Compound) resembles Hydroxyzine (Compound) and Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Cetirizine may cause a moderate interaction that could exacerbate diseases when taken with Trifluop... |
DB01142 | DB01359 | 1,264 | 729 | [
"DDInter593",
"DDInter1417"
] | Doxepin | Penbutolol | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high... | Moderate | 1 | [
[
[
1264,
24,
729
]
],
[
[
1264,
63,
461
],
[
461,
1,
729
]
],
[
[
1264,
24,
699
],
[
699,
40,
729
]
],
[
[
1264,
6,
6943
],
[
6943,
... | [
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timo... | Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol (Compound) resembles Penbutolol (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol (Compound) resembles Penbutolol (Compound)
Doxepin (Compound)... |
DB00011 | DB08889 | 1,451 | 350 | [
"DDInter944",
"DDInter299"
] | Interferon alfa-n1 | Carfilzomib | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combi... | Moderate | 1 | [
[
[
1451,
24,
350
]
],
[
[
1451,
24,
1060
],
[
1060,
63,
350
]
],
[
[
1451,
24,
482
],
[
482,
24,
350
]
],
[
[
1451,
63,
491
],
[
491,
... | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab... | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when... |
DB08901 | DB10795 | 1,468 | 221 | [
"DDInter1492",
"DDInter1486"
] | Ponatinib | Poliovirus type 1 antigen (formaldehyde inactivated) | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1468,
24,
221
]
],
[
[
1468,
63,
36
],
[
36,
24,
221
]
],
[
[
1468,
64,
581
],
[
581,
24,
221
]
],
[
[
1468,
24,
384
],
[
384,
2... | [
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with ... | Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Ponatinib may lead to a major life threatening interaction when taken with ... |
DB00063 | DB00814 | 366 | 1,171 | [
"DDInter659",
"DDInter1143"
] | Eptifibatide | Meloxicam | Synthetic cyclic hexapeptide that binds to platelet receptor glycoprotein and inhibits platelet aggregation. Derived from venom of the Southeastern pygmy rattlesnake (Sistrurus miliarus barbouri), eptifibatide is a cyclic heptapeptide that belongs to the class of arginin-glycin-aspartat-mimetics. | Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is ... | Moderate | 1 | [
[
[
366,
24,
1171
]
],
[
[
366,
24,
1027
],
[
1027,
40,
1171
]
],
[
[
366,
25,
936
],
[
936,
63,
1171
]
],
[
[
366,
24,
477
],
[
477,
... | [
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meloxicam"
]
],
[
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Piroxicam"
],
[
... | Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Piroxicam and Piroxicam (Compound) resembles Meloxicam (Compound)
Eptifibatide may lead to a major life threatening interaction when taken with Cangrelor and Cangrelor may cause a moderate interaction that could exacerbate dise... |
DB09291 | DB11642 | 741 | 938 | [
"DDInter1615",
"DDInter1480"
] | Rolapitant | Pitolisant | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Moderate | 1 | [
[
[
741,
24,
938
]
],
[
[
741,
63,
1413
],
[
1413,
24,
938
]
],
[
[
741,
64,
1670
],
[
1670,
24,
938
]
],
[
[
741,
24,
1499
],
[
1499,
... | [
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitolisant"
]
],
[
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fexofenadine"
],
[
... | Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Fexofenadine and Fexofenadine may cause a moderate interaction that could exacerbate diseases when taken with Pitolisant
Rolapitant may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may ca... |
DB01166 | DB09075 | 477 | 498 | [
"DDInter379",
"DDInter621"
] | Cilostazol | Edoxaban | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
477,
25,
498
]
],
[
[
477,
23,
944
],
[
944,
62,
498
]
],
[
[
477,
24,
41
],
[
41,
24,
498
]
],
[
[
477,
63,
109
],
[
109,
24,
... | [
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Cilostazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chamomile"
],
[
"Chamomile",
... | Cilostazol may cause a minor interaction that can limit clinical effects when taken with Chamomile and Chamomile may cause a minor interaction that can limit clinical effects when taken with Edoxaban
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilna... |
DB00388 | DB01576 | 1,636 | 93 | [
"DDInter1453",
"DDInter526"
] | Phenylephrine | Dextroamphetamine | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
1636,
24,
93
]
],
[
[
1636,
63,
73
],
[
73,
1,
93
]
],
[
[
1636,
63,
80
],
[
80,
40,
93
]
],
[
[
1636,
24,
1529
],
[
1529,
40,
... | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
... | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Amphetamine and Amphetamine (Compound) resembles Dextr... |
DB06810 | DB10897 | 397 | 539 | [
"DDInter1484",
"DDInter291"
] | Plicamycin | Capsicum | Plicamycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It has been used in the treatment of testicular cancer, Paget's disease of bone, and, rarely, the management of hypercalcemia. The manufacturer discontinued plicamycin in 2000. | Capsicum (Chili pepper) allergenic extract is used in allergenic testing. | Minor | 0 | [
[
[
397,
23,
539
]
],
[
[
397,
63,
885
],
[
885,
23,
539
]
],
[
[
397,
64,
553
],
[
553,
23,
539
]
],
[
[
397,
24,
578
],
[
578,
23,... | [
[
[
"Plicamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
]
],
[
[
"Plicamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
... | Plicamycin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a minor interaction that can limit clinical effects when taken with Capsicum
Plicamycin may lead to a major life threatening interaction when taken with Fondaparinux and Fondaparinux may ca... |
DB01045 | DB06335 | 463 | 761 | [
"DDInter1590",
"DDInter1646"
] | Rifampicin | Saxagliptin | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009. | Moderate | 1 | [
[
[
463,
24,
761
]
],
[
[
463,
6,
10417
],
[
10417,
45,
761
]
],
[
[
463,
25,
1491
],
[
1491,
63,
761
]
],
[
[
463,
63,
1573
],
[
1573,
... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCC1"
],
[
"ABCC1",
"{u} (Gene) is bound by {v} (Compound)",
... | Rifampicin (Compound) binds ABCC1 (Gene) and ABCC1 (Gene) is bound by Saxagliptin (Compound)
Rifampicin may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin
Rifampicin may cause a moderate... |
DB00358 | DB00559 | 1,010 | 152 | [
"DDInter1140",
"DDInter223"
] | Mefloquine | Bosentan | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortali... | Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure. | Moderate | 1 | [
[
[
1010,
24,
152
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
152
]
],
[
[
1010,
21,
29402
],
[
29402,
60,
152
]
],
[
[
1010,
63,
608
],
[
608,
... | [
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosentan"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bosentan (Compound)
Mefloquine (Compound) causes Hepatobiliary disease (Side Effect) and Hepatobiliary disease (Side Effect) is caused by Bosentan (Compound)
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00489 | DB00675 | 17 | 888 | [
"DDInter1704",
"DDInter1744"
] | Sotalol | Tamoxifen | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventric... | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Major | 2 | [
[
[
17,
25,
888
]
],
[
[
17,
24,
543
],
[
543,
63,
888
]
],
[
[
17,
24,
1376
],
[
1376,
64,
888
]
],
[
[
17,
21,
28640
],
[
28640,
6... | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
... | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhy... |
DB00524 | DB01132 | 811 | 1,130 | [
"DDInter1199",
"DDInter1472"
] | Metolazone | Pioglitazone | A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss. | Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus.[L11416,L11419,L11422,L11425] It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert _in ... | Moderate | 1 | [
[
[
811,
24,
1130
]
],
[
[
811,
21,
28996
],
[
28996,
60,
1130
]
],
[
[
811,
1,
359
],
[
359,
24,
1130
]
],
[
[
811,
24,
688
],
[
688,
... | [
[
[
"Metolazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"
]
],
[
[
"Metolazone",
"{u} (Compound) causes {v} (Side Effect)",
"Musculoskeletal discomfort"
],
[
"Musculoskeletal discomfor... | Metolazone (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Pioglitazone (Compound)
Metolazone (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazon... |
DB00794 | DB14568 | 759 | 982 | [
"DDInter1521",
"DDInter1000"
] | Primidone | Ivosidenib | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Ivosidenib is a first-in-class isocitrate dehydrogenase-1 (IDH1) inhibitor. IDH1 is an enzyme that is often mutated and overexpressed in some cancers, leading to aberrant cell growth and proliferation. Ivosidenib inhibits mutated IDH1, blocking the enzymatic activity and further differentiation of cancer cells. Ivoside... | Major | 2 | [
[
[
759,
25,
982
]
],
[
[
759,
24,
112
],
[
112,
23,
982
]
],
[
[
759,
64,
168
],
[
168,
23,
982
]
],
[
[
759,
62,
1101
],
[
1101,
2... | [
[
[
"Primidone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronida... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ivosidenib
Primidone may lead to a major life threatening interaction when taken with Bortezomib and Bortezomib may caus... |
DB01364 | DB01576 | 22 | 93 | [
"DDInter650",
"DDInter526"
] | Ephedrine | Dextroamphetamine | Ephedrine was first described in western literature in 1888, as a naturally occurring component of the ephedra plant, along with [pseudoephedrine]. Ephedrine acts as both a direct and indirect sympathomimetic. It is an alpha- and beta-adrenergic receptor agonist; however, it also causes the indirect release of norepine... | Dextroamphetamine is the dextrorotatory enantiomer of amphetamine. Dextroamphetamine was approved by the FDA in 2001 for the treatment of attention deficit hyperactivity disorder[L6010,Label]. | Moderate | 1 | [
[
[
22,
24,
93
]
],
[
[
22,
74,
73
],
[
73,
1,
93
]
],
[
[
22,
63,
80
],
[
80,
40,
93
]
],
[
[
22,
24,
1529
],
[
1529,
40,
93
... | [
[
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
]
],
[
[
"Ephedrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when ta... | Ephedrine (Compound) resembles Phentermine (Compound) and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine (Compound) resembles Dextroamphetamine (Compound)
Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Amph... |
DB08816 | DB09143 | 578 | 313 | [
"DDInter1802",
"DDInter1701"
] | Ticagrelor | Sonidegib | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagre... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Moderate | 1 | [
[
[
578,
24,
313
]
],
[
[
578,
63,
478
],
[
478,
24,
313
]
],
[
[
578,
24,
1478
],
[
1478,
24,
313
]
],
[
[
578,
24,
1375
],
[
1375,
... | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sonidegib"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
... | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor ... |
DB00241 | DB00348 | 288 | 254 | [
"DDInter257",
"DDInter1300"
] | Butalbital | Nitisinone | Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervou... | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Moderate | 1 | [
[
[
288,
24,
254
]
],
[
[
288,
24,
392
],
[
392,
63,
254
]
],
[
[
288,
25,
126
],
[
126,
63,
254
]
],
[
[
288,
1,
536
],
[
536,
63,
... | [
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
]
],
[
[
"Butalbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
... | Butalbital may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone
Butalbital may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a mode... |
DB00976 | DB01001 | 1,056 | 688 | [
"DDInter1758",
"DDInter1632"
] | Telithromycin | Salbutamol | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with ... | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Moderate | 1 | [
[
[
1056,
24,
688
]
],
[
[
1056,
64,
455
],
[
455,
24,
688
]
],
[
[
1056,
24,
1148
],
[
1148,
63,
688
]
],
[
[
1056,
6,
8374
],
[
8374,
... | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Salmeterol"
],
[
"Salm... | Telithromycin may lead to a major life threatening interaction when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline ... |
DB01309 | DB09389 | 1,254 | 517 | [
"DDInter933",
"DDInter1315"
] | Insulin glulisine | Norgestrel | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1254,
24,
517
]
],
[
[
1254,
63,
1130
],
[
1130,
23,
517
]
],
[
[
1254,
24,
52
],
[
52,
24,
517
]
],
[
[
1254,
63,
1645
],
[
1645,
... | [
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pioglitazone"... | Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Pioglitazone and Pioglitazone may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Dulag... |
DB00532 | DB06674 | 208 | 908 | [
"DDInter1152",
"DDInter837"
] | Mephenytoin | Golimumab | Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subuni... | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Moderate | 1 | [
[
[
208,
24,
908
]
],
[
[
208,
24,
1487
],
[
1487,
24,
908
]
],
[
[
208,
62,
608
],
[
608,
24,
908
]
],
[
[
208,
63,
1031
],
[
1031,
... | [
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],... | Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidoca... |
DB00530 | DB01149 | 1,195 | 851 | [
"DDInter667",
"DDInter1274"
] | Erlotinib | Nefazodone | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR)... | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Moderate | 1 | [
[
[
1195,
24,
851
]
],
[
[
1195,
6,
8374
],
[
8374,
45,
851
]
],
[
[
1195,
7,
3677
],
[
3677,
46,
851
]
],
[
[
1195,
18,
3365
],
[
3365,
... | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]
],
[
[
"Erlotinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Erlotinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nefazodone (Compound)
Erlotinib (Compound) upregulates NFKBIE (Gene) and NFKBIE (Gene) is upregulated by Nefazodone (Compound)
Erlotinib (Compound) downregulates LDHB (Gene) and LDHB (Gene) is downregulated by Nefazodone (Compound)
Erlotinib (Compou... |
DB09065 | DB11730 | 760 | 351 | [
"DDInter424",
"DDInter1588"
] | Cobicistat | Ribociclib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
760,
25,
351
]
],
[
[
760,
62,
271
],
[
271,
23,
351
]
],
[
[
760,
24,
466
],
[
466,
62,
351
]
],
[
[
760,
25,
283
],
[
283,
62,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mirabegron"
],
[
"Mirabegron",... | Cobicistat may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegron may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Daroluta... |
DB00065 | DB09389 | 581 | 517 | [
"DDInter923",
"DDInter1315"
] | Infliximab | Norgestrel | Infliximab is a tumor necrosis factor (TNF-alpha or TNF-α) blocker and a chimeric monoclonal IgG1 antibody composed of human constant (75%) and murine variable (25%) regions. Infliximab is produced by a recombinant cell line cultured by continuous perfusion. Tumor necrosis factor-alpha (TNF-α) is a key proinflammatory ... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
581,
24,
517
]
],
[
[
581,
24,
14
],
[
14,
23,
517
]
],
[
[
581,
25,
908
],
[
908,
24,
517
]
],
[
[
581,
24,
1031
],
[
1031,
24,... | [
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
... | Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Norgestrel
Infliximab may lead to a major life threatening interaction when taken with Golimumab and Golimumab may cause ... |
DB00373 | DB11126 | 461 | 900 | [
"DDInter1809",
"DDInter276"
] | Timolol | Calcium gluconate | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Moderate | 1 | [
[
[
461,
24,
900
]
],
[
[
461,
1,
729
],
[
729,
24,
900
]
],
[
[
461,
23,
542
],
[
542,
24,
900
]
],
[
[
461,
62,
1152
],
[
1152,
24... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium gluconate"
]
],
[
[
"Timolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a modera... | Timolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium gluconate
Timolol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a moderate interaction that ... |
DB00193 | DB08865 | 534 | 1,593 | [
"DDInter1841",
"DDInter448"
] | Tramadol | Crizotinib | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
534,
25,
1593
]
],
[
[
534,
6,
8374
],
[
8374,
45,
1593
]
],
[
[
534,
7,
5002
],
[
5002,
46,
1593
]
],
[
[
534,
7,
3250
],
[
3250,
... | [
[
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Tramadol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"... | Tramadol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Tramadol (Compound) upregulates SNAP25 (Gene) and SNAP25 (Gene) is upregulated by Crizotinib (Compound)
Tramadol (Compound) upregulates DNMT1 (Gene) and DNMT1 (Gene) is downregulated by Crizotinib (Compound)
Tramadol (Compound) ... |
DB00861 | DB08895 | 914 | 976 | [
"DDInter551",
"DDInter1825"
] | Diflunisal | Tofacitinib | Diflunisal, a salicylate derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with pharmacologic actions similar to other prototypical NSAIAs. Diflunisal possesses anti-inflammatory, analgesic and antipyretic activity. Though its mechanism of action has not been clearly established, most of its actions appear ... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Moderate | 1 | [
[
[
914,
24,
976
]
],
[
[
914,
24,
1017
],
[
1017,
63,
976
]
],
[
[
914,
63,
1512
],
[
1512,
24,
976
]
],
[
[
914,
24,
1479
],
[
1479,
... | [
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
... | Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclo... |
DB00490 | DB00902 | 946 | 104 | [
"DDInter254",
"DDInter1168"
] | Buspirone | Methdilazine | Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic dr... | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
946,
24,
104
]
],
[
[
946,
63,
13
],
[
13,
24,
104
]
],
[
[
946,
24,
820
],
[
820,
1,
104
]
],
[
[
946,
24,
537
],
[
537,
40,
... | [
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
... | Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine a... |
DB00317 | DB00673 | 883 | 723 | [
"DDInter810",
"DDInter112"
] | Gefitinib | Aprepitant | Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer. Acting in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. | Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective h... | Moderate | 1 | [
[
[
883,
24,
723
]
],
[
[
883,
24,
875
],
[
875,
40,
723
]
],
[
[
883,
6,
7524
],
[
7524,
45,
723
]
],
[
[
883,
21,
28770
],
[
28770,
... | [
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
]
],
[
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosaprepitant"
],
[
... | Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Fosaprepitant and Fosaprepitant (Compound) resembles Aprepitant (Compound)
Gefitinib (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Aprepitant (Compound)
Gefitinib (Compound) causes Haematuria (Side Effect) and Haema... |
DB00816 | DB06176 | 1,674 | 1,342 | [
"DDInter1346",
"DDInter1616"
] | Orciprenaline | Romidepsin | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
1674,
24,
1342
]
],
[
[
1674,
24,
956
],
[
956,
24,
1342
]
],
[
[
1674,
63,
485
],
[
485,
24,
1342
]
],
[
[
1674,
24,
1616
],
[
1616,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norfloxacin"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine a... |
DB00252 | DB00414 | 362 | 590 | [
"DDInter1460",
"DDInter16"
] | Phenytoin | Acetohexamide | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Moderate | 1 | [
[
[
362,
24,
590
]
],
[
[
362,
24,
660
],
[
660,
62,
590
]
],
[
[
362,
25,
1017
],
[
1017,
63,
590
]
],
[
[
362,
1,
651
],
[
651,
63... | [
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetohexamide"
]
],
[
[
"Phenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[... | Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Acetohexamide
Phenytoin may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cau... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.